Effect of EARLY administration of DEXamethasone in patients with COVID-19 pneumonia without acute hypoxemic respiratory failure and risk of development of acute respiratory distress syndrome (EARLY-DEX COVID-19): study protocol for a randomized controlled trial

BACKGROUND: Corticosteroids are one of the few drugs that have shown a reduction in mortality in coronavirus disease 2019 (COVID-19). In the RECOVERY trial, the use of dexamethasone reduced 28-day mortality compared to standard care in hospitalized patients with suspected or confirmed COVID-19 requi...

Descripción completa

Detalles Bibliográficos
Autores principales: Franco-Moreno, Anabel, Acedo-Gutiérrez, María Soledad, Martín, Nicolás Labrador-San, Hernández-Blanco, Clara, Rodríguez-Olleros, Celia, Ibáñez-Estéllez, Fátima, Suárez-Simón, Ana, Balado-Rico, Mateo, Romero-Paternina, Ana Rocío, Alonso-Menchén, David, Escolano-Fernández, Belén, Piniella-Ruiz, Esther, Alonso-Monge, Ester, Notario-Leo, Helena, Bibiano-Guillén, Carlos, Peña-Lillo, Gabriela, Antiqueira-Pérez, Armando, Romero-Pareja, Rodolfo, Cabello-Clotet, Noemí, Estrada-Pérez, Vicente, Troya-García, Jesús, de Carranza-López, María, Escobar-Rodríguez, Ismael, Vallejo-Maroto, Nacho, Torres-Macho, Juan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9479245/
https://www.ncbi.nlm.nih.gov/pubmed/36109825
http://dx.doi.org/10.1186/s13063-022-06722-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9479245/
https://www.ncbi.nlm.nih.gov/pubmed/36109825
http://dx.doi.org/10.1186/s13063-022-06722-x

Ejemplares similares